- Home
- TLPH vs AIMD Comparison
TLPH vs AIMD Comparison
Compare TLPH & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- AIMD
- Stock Information
- Founded
- TLPH 2005
- AIMD 1984
- Country
- TLPH United States
- AIMD United States
- Employees
- TLPH N/A
- AIMD N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- AIMD Health Care
- Exchange
- TLPH Nasdaq
- AIMD Nasdaq
- Market Cap
- TLPH 10.6M
- AIMD 11.9M
- IPO Year
- TLPH 2011
- AIMD N/A
- Fundamental
- Price
- TLPH $0.42
- AIMD $2.58
- Analyst Decision
- TLPH Strong Buy
- AIMD
- Analyst Count
- TLPH 1
- AIMD 0
- Target Price
- TLPH $6.00
- AIMD N/A
- AVG Volume (30 Days)
- TLPH 919.9K
- AIMD 89.9K
- Earning Date
- TLPH 08-13-2025
- AIMD 08-04-2025
- Dividend Yield
- TLPH N/A
- AIMD N/A
- EPS Growth
- TLPH N/A
- AIMD N/A
- EPS
- TLPH N/A
- AIMD N/A
- Revenue
- TLPH $27,000.00
- AIMD $106,207.00
- Revenue This Year
- TLPH N/A
- AIMD N/A
- Revenue Next Year
- TLPH $14,533.26
- AIMD N/A
- P/E Ratio
- TLPH N/A
- AIMD N/A
- Revenue Growth
- TLPH N/A
- AIMD 13.38
- 52 Week Low
- TLPH $0.38
- AIMD $2.00
- 52 Week High
- TLPH $1.19
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- TLPH 42.40
- AIMD 40.82
- Support Level
- TLPH $0.38
- AIMD $2.55
- Resistance Level
- TLPH $0.79
- AIMD $2.85
- Average True Range (ATR)
- TLPH 0.06
- AIMD 0.18
- MACD
- TLPH -0.00
- AIMD -0.04
- Stochastic Oscillator
- TLPH 10.51
- AIMD 12.39
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.